About
iCare RETCAD is a clinical-grade AI software solution developed by iCare (a Revenio Group brand) that brings artificial intelligence to retinal diagnostics. Designed for ophthalmology clinics, screening centers, and teleophthalmology programs, RETCAD automatically analyzes retinal fundus images to identify early markers of sight-threatening conditions including diabetic retinopathy (DR), age-related macular degeneration (AMD), and glaucoma. As part of the broader iCare Screening Solution, RETCAD enables fully automated image acquisition and AI-driven processing, significantly increasing throughput while maintaining diagnostic accuracy. The system integrates with iCare's range of fundus imaging devices—such as the iCare DRSplus and the iCare EIDON family—to provide a seamless end-to-end workflow from image capture to AI-generated analysis and referral recommendations. By automating the grading process, RETCAD helps clinicians prioritize high-risk patients, reduce manual review burden, and enable timely clinical intervention. The system is especially valuable in population-level diabetic eye screening programs, where fast and reliable triage is essential. Its AI algorithms are backed by clinical validation and designed to reduce unnecessary referrals while ensuring at-risk patients receive prompt attention. iCare RETCAD is suitable for hospitals, eye care clinics, and national screening initiatives looking to modernize and scale their retinal disease detection programs.
Key Features
- AI-Powered Retinal Analysis: Automatically analyzes fundus images using trained AI algorithms to detect signs of retinal pathology with clinical-grade accuracy.
- Multi-Disease Detection: Simultaneously screens for diabetic retinopathy (DR), age-related macular degeneration (AMD), and glaucoma from a single image set.
- Automated Referral Flow: Generates structured referral recommendations based on AI findings, helping clinicians prioritize high-risk patients efficiently.
- Seamless iCare Ecosystem Integration: Integrates directly with iCare fundus imaging devices (DRSplus, EIDON family) and iCare ILLUME for a fully connected screening workflow.
- High-Throughput Screening: Designed to handle large patient volumes, making it ideal for national diabetic eye screening programs and busy ophthalmology practices.
Use Cases
- Automated diabetic retinopathy screening in national or regional eye health programs, enabling early detection and timely referral for thousands of patients.
- Triage support in busy ophthalmology clinics, where AI-driven grading reduces the manual workload of reviewing large volumes of fundus images.
- Teleophthalmology programs using iCare OCULO, where RETCAD provides remote AI analysis of uploaded retinal images without an on-site specialist.
- Integration into annual eye exams for diabetic patients, ensuring consistent and objective monitoring of retinal health over time.
- Hospital and healthcare network deployments seeking to standardize retinal screening protocols and reduce variability in disease detection across multiple sites.
Pros
- Clinically Validated AI: The AI algorithms are backed by clinical studies, providing reliable and reproducible results for diagnostic support.
- End-to-End Automation: From image capture to AI grading and referral triage, the workflow is fully automated, reducing manual workload on clinical staff.
- Broad Disease Coverage: Detects three major sight-threatening conditions in a single pass, maximizing the value of each screening session.
- Scalable for Population Screening: Suited for large-scale screening programs, helping healthcare systems manage growing demand for diabetic eye checks.
Cons
- Hardware Dependency: Optimal performance requires compatible iCare fundus imaging devices, limiting flexibility for clinics using third-party cameras.
- Enterprise-Only Pricing: Pricing is not publicly disclosed and is tailored to institutional buyers, making it inaccessible for individual practitioners or small clinics on tight budgets.
- Limited to Retinal Pathologies: RETCAD focuses specifically on retinal disease detection and does not cover other areas of ophthalmic diagnostics like corneal or anterior segment analysis.
Frequently Asked Questions
What diseases can iCare RETCAD detect?
iCare RETCAD is designed to detect three major retinal conditions: diabetic retinopathy (DR), age-related macular degeneration (AMD), and glaucoma, using AI analysis of fundus images.
Does iCare RETCAD require specific hardware?
Yes, iCare RETCAD is optimized to work with iCare's fundus imaging devices, such as the iCare DRSplus and iCare EIDON family, for best results within the iCare Screening Solution ecosystem.
Is iCare RETCAD suitable for large screening programs?
Absolutely. iCare RETCAD is built for high-throughput environments, making it ideal for national diabetic eye screening programs, hospital networks, and busy ophthalmology clinics.
How does iCare RETCAD fit into the iCare Screening Solution?
RETCAD is a core AI analysis component within iCare Screening Solution. It works alongside iCare ILLUME (screening management) and iCare OCULO (teleophthalmology) to provide a fully automated pathway from imaging to referral.
Is iCare RETCAD a replacement for a human ophthalmologist?
No, iCare RETCAD is a decision-support tool designed to assist clinicians. It automates the initial grading process and flags at-risk patients, but final clinical decisions remain with qualified eye care professionals.
